Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Dyno7on Mar 12, 2018 7:48pm

145 Views

Post# 27703787

RE:Philippe Dubuc, chef de la direction financière de Theratech

LES CHIFFRES:

600,000 patients traits aux anti-viraux aux USA
4% de ceux-ci sont rsistants au traitement
20,000 25,000 patients cibles pour le Trogarzo
118,000$ US par anne pour le Trogarzo
March potentiel 5 10 fois les ventes d'Egrifta qui ont t de 43,000,000$

Bullboard Posts

Visionstate set to leverage success in the U.S. market